Urine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancer
用于胰腺癌早期诊断和风险评估的尿液和血清生物标志物
基本信息
- 批准号:10339431
- 负责人:
- 金额:$ 62.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-02-03 至 2026-01-31
- 项目状态:未结题
- 来源:
- 关键词:AccountingAddressAlgorithmsBenignBiological MarkersBlindedCancer EtiologyCessation of lifeChineseClassificationClinicalClinical ResearchCohort StudiesCommunitiesCurative SurgeryDataDevelopmentDiagnosisDiagnosticDifferential DiagnosisDiscriminationDiseaseEarly DiagnosisEnvironmentExcisionFutureGeneral PopulationGenesGoalsHealthIncidenceIndividualInstitutionInterventionLiquid substanceMagnetic Resonance ImagingMalignant NeoplasmsMalignant neoplasm of pancreasMinorityNurses&apos Health StudyOperative Surgical ProceduresOrganOutcomePancreasPancreatic AdenocarcinomaPancreatic Ductal AdenocarcinomaPathologyPatient CarePatientsPerformancePersonsPhasePopulationProbabilityPrognosisProspective StudiesProspective cohortProspective cohort studyResearchResectableRetrospective cohortRiskRisk AssessmentSamplingSavingsSensitivity and SpecificitySerumSerum ProteinsSingaporeSiteSourceSpecificitySurvival RateSymptomsTestingTimeTrainingTranslationsUrineValidationWorkbasebiomarker panelcandidate markercare costsclinical diagnosisclinically translatablecohortcombinatorialcostearly detection biomarkersexosomehigh riskhigh risk populationimprovedinnovationmortalitynovelnovel diagnosticspatient subsetsprospectiveprotein biomarkersscreeningscreening guidelinesspecific biomarkerssurveillance strategytumorurinary
项目摘要
ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, primarily due to most cases being
diagnosed at an advanced, incurable stage. While 5-year survival of metastatic PDAC is <5%, outcomes
dramatically improve for localized PDAC. Poor prognosis is due to a lack of biomarkers for diagnosing PDAC at
an early, asymptomatic stage when cure is possible. Effective diagnosis of early stage PDAC depends on
identification of accurate, non-invasive biomarkers in combination with a strategy for screening increased risk
populations. Our primary objective is to identify non-invasive protein biomarkers in serum, urine, and exosomes
that accurately distinguish between patients with and without early stage resectable PDAC that is amenable to
curative surgery. Novel diagnostics would also improve discrimination between PDAC and benign pancreatic
pathologies. The goal of the proposed research is to develop clinically translatable noninvasive biomarkers-
based tests for screening (in high risk groups) and differential diagnosis of PDAC. Our central hypothesis is that
combinations of urinary, serum, and exosome derived biomarkers could be synergistic offering a superior
classification power. We have used urine and serum samples from retrospective and prospective cohort studies
to identify a range of strong candidate combinatorial multimarker algorithms for early detection and diagnosis of
PDAC. In Aim 1, we will optimize the performance of a PDAC differential diagnosis algorithm and will validate
the optimized algorithm in samples collected prior to clinical diagnosis in the Pancreatic Adenocarcinoma Gene
Environment Risk (PAGER) study. In Aim 2, we will optimize the performance of an early detection algorithm for
resectable PDAC in pre-diagnostic samples from three prospectively collected cohorts and validate the optimized
EDA in blinded parallel serum/urine samples from the Southern Community Cohort Study (SCCS). If successful,
our project will yield novel, validated algorithms for risk assessment and early detection and for differential
diagnosis of PDAC. These algorithms when combined will result in a new pioneering screening paradigm for
PDAC allowing for timely live-saving interventions. Our strong preliminary data, powerful and synergistic
investigative team, and the availability of parallel urine and serum samples from unique prospective cohorts
contribute to the high probability of successful accomplishing the proposed studies.
摘要
胰腺导管腺癌(PDAC)是最致命的癌症之一,主要是由于大多数病例是在胰腺癌中发生的。
在晚期无法治愈的阶段被确诊虽然转移性PDAC的5年生存率<5%,但结局
显著改善局部PDAC。预后不良是由于缺乏诊断PDAC的生物标志物
可能治愈的早期无症状阶段。早期PDAC的有效诊断取决于
识别准确的非侵入性生物标志物,并结合筛查风险增加的策略
人口。我们的主要目标是确定血清、尿液和外泌体中的非侵入性蛋白质生物标志物
准确区分有和没有早期可切除PDAC的患者,
治疗性手术新的诊断方法也将提高PDAC和良性胰腺癌之间的区分
病理学拟议研究的目标是开发临床可翻译的非侵入性生物标志物-
用于筛查(高危人群)和PDAC鉴别诊断的基础测试。我们的核心假设是,
尿、血清和外来体来源的生物标志物的组合可以是协同的,提供上级生物标志物。
分类能力我们使用了来自回顾性和前瞻性队列研究的尿液和血清样本
鉴定一系列强候选组合多标记算法用于早期检测和诊断
PDAC。在目标1中,我们将优化PDAC鉴别诊断算法的性能,并将验证
胰腺癌基因临床诊断前采集样本的优化算法
环境风险(PAGER)研究。在目标2中,我们将优化早期检测算法的性能,
可切除的PDAC在三个前瞻性收集的队列的诊断前样本,并验证优化的
来自南方社区队列研究(SCCS)的设盲平行血清/尿液样本中的EDA。如果成功,
我们的项目将产生新的,有效的算法,用于风险评估和早期检测,
PDAC的诊断这些算法结合在一起,将产生一个新的开拓性的筛选范式,
PDAC允许及时采取挽救生命的干预措施。我们强大的初步数据,强大的协同作用
研究团队,以及来自独特前瞻性队列的平行尿液和血清样本的可用性
有助于成功完成拟议研究的高概率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Surinder K. Batra其他文献
Functions of tumorigenic and migrating cancer progenitor cells in cancer progression and metastasis and their therapeutic implications
- DOI:
10.1007/s10555-007-9052-4 - 发表时间:
2007-02-02 - 期刊:
- 影响因子:8.700
- 作者:
Murielle Mimeault;Surinder K. Batra - 通讯作者:
Surinder K. Batra
Wolfram 症候群の実態調査
关于 Wolfram 综合征的事实调查
- DOI:
- 发表时间:
2011 - 期刊:
- 影响因子:0
- 作者:
Yukihiro Tamura;Michiyo Higashi;Sho Kitamoto;Seiya Yokoyama;Masahiko Osako;Michiko Horinouchi;Takeshi Shimizu;Mineo Tabata;Surinder K. Batra;Masamichi Goto;Suguru Yonezawa;松永仁恵,田部勝也,太田康晴,奥屋 茂,和田安彦,山田祐一郎,雨宮 伸,杉原茂孝,岡 芳知,谷澤幸生 - 通讯作者:
松永仁恵,田部勝也,太田康晴,奥屋 茂,和田安彦,山田祐一郎,雨宮 伸,杉原茂孝,岡 芳知,谷澤幸生
PP01.05 Targeting MUC16-Mediated KRASi Resistance in NSCLC
PP01.05 针对非小细胞肺癌中 MUC16 介导的 KRASi 耐药性
- DOI:
10.1016/j.jtho.2025.03.013 - 发表时间:
2025-04-01 - 期刊:
- 影响因子:20.800
- 作者:
Ashu Shah;Shamema Salam;Sanjib Chaudhary;Iniyan A. Muthamil;Imayavaramban Lakshmanan;Surinder K. Batra;Apar K. Ganti - 通讯作者:
Apar K. Ganti
Mo1138 COMPARATIVE PROTEOMICS REVEALS TRANSLATIONAL POTENTIAL OF TARGETS FOR PANCREATIC DUCTAL ADENOCARCINOMA
- DOI:
10.1016/s0016-5085(23)02780-4 - 发表时间:
2023-05-01 - 期刊:
- 影响因子:
- 作者:
Mathilde Resell;Hanne-Line Rabben;Manoj Amrutkar;Lars Hagen;Surinder K. Batra;Caroline S. Verbeke;Timothy C. Wang;Duan Chen;Chun-Mei Zhao - 通讯作者:
Chun-Mei Zhao
MUC5AC in stromal heterogeneity and the Progression of Pancreatic Cancer
- DOI:
10.1016/j.canlet.2023.216541 - 发表时间:
2024-01-28 - 期刊:
- 影响因子:
- 作者:
Surinder K. Batra - 通讯作者:
Surinder K. Batra
Surinder K. Batra的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Surinder K. Batra', 18)}}的其他基金
Truncated O-glycan-dependent mechanisms inducing metastatic dissemination in pancreatic cancer
截短的O-聚糖依赖性机制诱导胰腺癌转移扩散
- 批准号:
10683305 - 财政年份:2022
- 资助金额:
$ 62.64万 - 项目类别:
Molecular Imaging Probe(s) for Optical Surgical Navigation of Pancreatic Cancer
用于胰腺癌光学手术导航的分子成像探针
- 批准号:
10557180 - 财政年份:2022
- 资助金额:
$ 62.64万 - 项目类别:
Molecular Imaging Probe(s) for Optical Surgical Navigation of Pancreatic Cancer
用于胰腺癌光学手术导航的分子成像探针
- 批准号:
10367553 - 财政年份:2022
- 资助金额:
$ 62.64万 - 项目类别:
Connectivity mapping identified novel combination therapy for glioblastoma
连接映射确定了胶质母细胞瘤的新型联合疗法
- 批准号:
10504826 - 财政年份:2022
- 资助金额:
$ 62.64万 - 项目类别:
Connectivity mapping identified novel combination therapy for glioblastoma
连接映射确定了胶质母细胞瘤的新型联合疗法
- 批准号:
10686268 - 财政年份:2022
- 资助金额:
$ 62.64万 - 项目类别:
Truncated O-glycan-dependent mechanisms inducing metastatic dissemination in pancreatic cancer
截短的O-聚糖依赖性机制诱导胰腺癌转移扩散
- 批准号:
10503433 - 财政年份:2022
- 资助金额:
$ 62.64万 - 项目类别:
Urine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancer
用于胰腺癌早期诊断和风险评估的尿液和血清生物标志物
- 批准号:
10156494 - 财政年份:2021
- 资助金额:
$ 62.64万 - 项目类别:
Urine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancer
用于胰腺癌早期诊断和风险评估的尿液和血清生物标志物
- 批准号:
10551280 - 财政年份:2021
- 资助金额:
$ 62.64万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 62.64万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 62.64万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 62.64万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 62.64万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 62.64万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 62.64万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 62.64万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 62.64万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 62.64万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 62.64万 - 项目类别:
Research Grant